Veins articles

ACC 2020 Virtual | Sub-análisis del COMPASS: la diabetes aumenta el beneficio del rivaroxaban más AAS

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses of rivaroxaban and aspirin vs. aspirin alone.  This analysis was pre-specified in the COMPASS protocol and was presented virtually for the ACC 2020 and simultaneously published in Circulation. Patients with diabetes, showed numerically greater reduction in terms of

isquemia crítica de miembros inferiores

New European Guidelines on the Management of Lower Limb Acute Ischemia

Clinical practice guidelines are usually tedious and, frankly, while a lot of people make an enormous effort to write them, they are ultimately read in full by just a few. These new European Guidelines on the Management of Lower Limb Acute Ischemia represent a special team effort, since they include physicians, cardiologists, surgeons, and interventionists,

HIV and Peripheral Artery Disease: Acknowledging the Association

The role of human immunodeficiency virus (HIV) in the development of vascular disease (specifically peripheral artery disease) remains unclear. Is the virus per se the direct cause of this disease or is it a consequence of dyslipidemia, one of the adverse effects of antiretrovirals? This study looked into the effect of HIV infection on peripheral

Antithrombotics after Venous Stenting: Rather Different from Coronary Artery Stenting

Should the Antithrombotic/antiplatelet therapy following 10.0 by 60 mm stent implantation to the subclavian vein of a chronic kidney patient be the same as one following a 3.0 by 18 mm stent implantation to the second segment of the left anterior descending artery of this same patient? The daily practice of many interventional cardiologists performing

What’s New in the European Guidelines on Peripheral Arterial Disease

Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease in 2011, there have been many trials and registries that warrant guideline adjustments in many aspects. The first novelty is the teamwork that gave way to these guidelines, which were written in collaboration with the European Society of

Statin Pre-Treatment for the Prevention of Peri-Procedural Events in Carotid Artery Stenting

What is the effect of statins on amputations, and survival in peripheral vascular disease?

The prevalence of peripheral arterial disease is between 15% and 20% of patients older than 65 years and its severity is greatly underestimated. In fact, annual mortality is higher in patients with peripheral arterial disease (8.2%) than in those after acute myocardial infarction (6.3%). Despite the above, medical advice and efforts to modify risk factors

Inferior Vena Cava Filters in Recurrent Thromboembolism: Yes or No?

Courtesy of Dr. Guillermo Migliaro. At present, there is no clear evidence in favor of inferior vena cava filters (IVC) for patients developing recurrent symptomatic venous thromboembolism (VTE), and the existing guideline recommendations from the different societies are contradicting.   The aim of this study was to assess the effectiveness of these devices in patients

Mortality Reduction with Vena Cava Filters

Original Title: Outcomes after Vena Cava Filter Use in Non-Cancer Patients with Acute Venous Thromboembolism: A Population-Based Study. Reference: Richard H. White et al. Circulation. 2016 Apr 5. Epub ahead of print. The evidence on the benefits of vena cava filters is limited. This retrospective study analyzed all patients with baseline oncological processes admitted to

Filter use in inferior vena cava for unstable elderly patients with pulmonary embolism reduces mortality.

Original title: Vena cava filters in unstable elderly patients with acute pulmonary embolism Reference: Stein PD et al. Am J Med. 2014 Mar;127(3):222-5.   Filters in inferior vena cava may reduce mortality in patients with severe pulmonary embolism (PE) who are hemodynamically unstable. This has not been demonstrated in elderly patients, a growing demographic group where the

Prophylactic vena cava filters in trauma patients effectively reduces pulmonary embolism

Original title: The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. Reference: Haut ER et al. JAMA Surg. 2014;149:194-202. Trauma is one of the strongest risk factors for pulmonary embolism (PE). Current guidelines recommend low molecular weight heparin therapy which have been proved effective; however, trauma patients often present high risk

Top